References
- Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012;13(8):790–801. doi:https://doi.org/10.1016/S1470-2045(12)70211-5.
- Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, et al. The global burden of women’s cancers: a grand challenge in global health. Lancet. 2017;389(10071):847–60. doi:https://doi.org/10.1016/S0140-6736(16)31392-7.
- Shulman LN, Willett W, Sievers A, Knaul FM. Breast cancer in developing countries: opportunities for improved survival. J Oncol. 2010;2010:595167. doi:https://doi.org/10.1155/2010/595167.
- Ramaswami R, Paulino E, Barrichello A, Nogueira-Rodrigues A, Bukowski A, St. Louis J, et al. Disparities in breast, lung, and cervical cancer trials worldwide. JGO. 2018;4(4):1–11. doi:https://doi.org/10.1200/JGO.17.00226.
- Desai A, Kuderer NM, Lyman GH. Aligning cancer clinical trials with cancer burden: need for greater global leadership, resources, and vision. JAMA Oncol. 2021;7(3):357. doi:https://doi.org/10.1001/jamaoncol.2020.7293.
- Vaidyanathan G. India’s clinical trials rules to speed up drug approvals. Nature. 2019. doi:https://doi.org/10.1038/d41586-019-01054-4.
- Butterbaugh S, Roy AM, Hasanein H, Patel RA, Mathew A. Prospective registration of cancer clinical trials in India. JCO. 2018;36(15_suppl):e18863–e18863. doi:https://doi.org/10.1200/JCO.2018.36.15_suppl.e18863.
- Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. J Natl Cancer Inst. 2019;111(3):245–55. doi:https://doi.org/10.1093/jnci/djy221.
- Vaidyanathan G. Failings exposed at India’s drug regulator. Nature. 2012;18. doi:https://doi.org/10.1038/d41586-019-01054-4.
- Sabha Poir. Fifty-ninth report on the functioning of the central drugs standard control organisation (CDSCO). 2012. [cited 2021 Feb 12]. http://164.100.47.5/newcommittee/reports/englishcommittees/committee%20on%20health%20and%20family%20welfare/59.pdf.
- Srinivasan SnAJ, Amar%D. Standing committee report on CDSCO: hard facts confirm an open secret. Vol 9. doi:https://doi.org/10.20529/IJME.2012.049.
- Times H. 88 clinical trial volunteers died in 4 years due to direct side effects: Health ministry data. 2019. https://www.hindustantimes.com/mumbai-news/88-clinical-trial-volunteers-died-in-4-years-due-to-direct-side-effects-health-ministrydata/story-4Q3vRXBbyMsWlvPBn8MaHO.html
- Urooj M, Husain GM, Khan MA, Kazmi MH. Compensation to clinical trial participants in India: A gap analysis. Int J Pharm Investig. 2017;7(2):41–46. doi:https://doi.org/10.4103/jphi.JPHI_31_17.
- Jesani A, Srinivasan S. New drugs and clinical trials rules, 2019: the market trumps ethics and participant rights. Indian J Med Ethics. 2019;4(2):89–91.
- Solutions G. WHO tells govt strict clinical trial rules will drive away drug firms. 2018. https://www.livemint.com/Industry/pdHu6zfNmDDCnHDbh1svVP/WHO-tells-govt-strict-clinical-trial-rules-will-drive-away-d.html
- Sharma DC. Rights violation found in HPV vaccine studies in India. Lancet Oncol. 2013;14(11):e443. doi:https://doi.org/10.1016/S1470-2045(13)70420-0.
- LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ. 2011;89(11):821–30. doi:https://doi.org/10.2471/BLT.11.089862.
- India CDSCODGoHSMoHaFWGo. Frequently Asked Questions (FAQs) on new drugs and clinical trials. [cited 2021 Feb 12]. https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPublic_NoticesFiles/faqnd.pdf.